The Human Leukocyte Differentiation Antigen workshop Ⅷ, held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice.
HLDA8 adopted the aims and methodology established at previous workshops. The major aims were (1) to assign CD names to molecules for which good-quality antibodies (at least one) and good molecular data are available (generally meaning that the molecule has been cloned); (2) to validate new antibodies against existing CD molecules; (3) to evaluate a "blind panel" of new monoclonal antibodies with a view to identifying new molecules by cluster analysis, following the traditional approach described above; and (4) to provide a forum for discussing and developing scientific understanding and practical applications of leukocyte differentiation molecules, including their ligands.
HLDA8 were added 95 new molecules to the list of CD antigens, shown in new CD antigens list.
The question of whether HLDA has reached the point of diminishing returns is raised after every workshop. However, there is good reason to believe we have so far accounted for just a fraction of the molecules expressed on leukocyte surfaces and the 95 new designations of HLDA8 support that view.
| New CD | Alias | Function |
|---|---|---|
| CDw113 | ||
| CD118 | LIFR, gp190 | Regulates a variety of biological responses including cell proliferation, apoptosis, chemotaxis and adhesion |
| CDw156C | ||
| CD159c | ||
| CD172b | SIRPβ, SIRB1 | Immunoglobulin-like cell surface receptor for CD47. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. |
| CD172g | SIRPγ, SIRPB2 | Immunoglobulin-like cell surface receptor that mediates cell-cell adhesion on binding with CD47 |
| CD181 | ||
| CD182 | ||
| CD185 | CXCR5, BLR1 | Homing and cell movement |
| CDw186 | ||
| CD191 | CCR1, MIP-1αR, RANTES-R | Chemotaxis, adhesion |
| CD192 | CCR2, MCP-1-R | Leukocyte chemotaxis and is an HIV co-receptor |
| CD193 | ||
| CD196 | CCR6, BN-1, CKR-L3, CKRL3, CMKBR6, DCR2, DRY6, GPR29, GPRCY4, STRL22 | Receptor for a C-C type chemokine. Binds to MIP-3-alpha/LARC and affects dendritic cell chemotaxis. |
| CD197 | ||
| CDw198 | ||
| CDw199 | ||
| CDw218a | ||
| CDw218b | ||
| CD248 | ||
| CD249 | Aminopeptidase AM, EAP, ENPEP | Converts angiotensin II to angiotensin III. |
| CD252 | OX40L, gp34 | Ligand for receptor TNFRSF4. Co-stimulates T-cell proliferation and cytokine production |
| CD253 | TRAIL, Apo-2L, TL2, TNFSF10 | Induces cell death by apoptosis |
| CD254 | TNFSF11, RANKL, OPGL, ODF | Involved in dendritic cell maturation |
| CD256 | APRIL, TALL-2, TRDL-1, TNFSF13 | Important for B cell development |
| CD257 | BLyS, BAFF, TALL-1, TNFSF13B | Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity |
| CD258 | LIGHT, HVEM-L, TNFRSF14 | Stimulates T-cell proliferation, receptor for Herpes simplex virus |
| CD261 | TRAIL-R1, DR4, TNFRSF10A | Induces apoptosis, promotes activation of NFkB |
| CD262 | TRAIL-R2, DR5, TNFRSF10B | Activated by TNFSF10 / TRAIL and transduces apoptosis signal |
| CD263 | ||
| CD264 | DCR2, TRAIL-R4, TNFRSF10D | Receptor for TRAIL, inhibits apoptosis |
| CD265 | RANK, TRANCE-R, ODFR, TNFRSF11A | Receptor for TRANCE. Enhances T-cell growth and dendritic cell function, plays a role in lymph node organogenesis |
| CD266 | TWEAK-R, FGF-inducible 14, TNFRSF12A | Receptor for TWEAK. Promotes angiogenesis and the proliferation of endothelial cells. |
| CD267 | TACI, TNFR SF13B, TNFRSF13B | Receptor for CD256 and CD257, mediates activation of the transcription factors NFAT, AP1, and NFkB. |
| CD268 | BAFFR, TR13C,TNFRSF13C | B-cell receptor for CD257. B-cell response |
| CD269 | BCMA, TNFRSF13B, TNFRSF17 | Receptor for CD256 and CD257, activates NFkB and JNK. |
| CD271 | NGFR, p75 (NTR) | Regulates neuronal growth, migration, differentiation and cell death during stem cells. |
| CD272 | BTLA | Lymphocyte inhibitory receptor |
| CD273 | B7DC, PD-L2, PDCD1L2 | Stimulatory on dendritic cells, inhibits T-cell activation upon engaging the PD1 receptor. |
| CD274 | B7-H1, PD-L1 | Found on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition |
| CD275 | B7-H2, ICOSL, B7-RP1, GL50 | Ligand for CD278. Costimulatory signal for T-cell proliferation and cytokine secretion, induces B-cell proliferation and differentiation |
| CD276 | B7-H3 | Enhances the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling |
| CD277 | BTN3A1, butyrophilin SF3 A1, BTF5 | T-cell activation |
| CD278 | ICOS, AILIM | Mediate cell-cell interactions, and effective help for antibody secretion by B-cells |
| CD279 | PD1, SLEB2 | Inhibitory cell surface receptor involved in T-cell tolerance |
| CD280 | ||
| CD281 | TLR1 | Pathogen recognition and activation of innate immunity, regulates TLR2 function |
| CD282 | TLR2 | Mediator of innate immunity against bacterial cell wall lipoproteins. Induces activation of NFkB |
| CD283 | TLR3 | Mediator of innate immunity against viral infection, activated by dsDNA |
| CD284 | TLR4 | Mediator to innate immunity against bacterial polysaccharides. Induces activation of NFkB and production of type I interferons |
| CD289 | ||
| CD292 | BMPR1A, ALK3, SKR5 | Receptor for BMP-2 and BMP-4 |
| CDw293 | ||
| CD294 | ||
| CD295 | LeptinR, LEPR, OB-R, Leptin Receptor | Receptor for leptin. Involved in the regulation of fat metabolism and required for normal lymphopoiesis |
| CD296 | ART1, ARTC1 | Catalyzes the transfer of ADP-ribose from NAD+ to arginine residues in proteins |
| CD297 | ART4, dombrock blood group | Plays a role in the metabolism of Dombrock blood group antigen |
| CD298 | ATP1B3, ATPB-3 | Component of Na+-K+ pump on neuronal membranes. |
| CD299 | DC-SIGN-related, LSIGN, DC-SIGN2, CLEC4M, DC-SIGNR | Pathogen-recognition receptor involved in peripheral immune surveillance in liver. Recognizes mannose N-linked oligosaccharides in HIV-1, HIV-2, human cytomegalovirus and human SARS coronavirus |
| CD300a | CMRF35H, IRC1, IRp60M, CLM-8 | NK cell function; also suppresses the effects of eotaxin, IL-5 and GM-CSF on neutrophils; and inhibits Ig-E dependent |
| CD300c | CMRF35A, LIR, CLM-6 | Regulates IFN-alpha and TNF-alpha secretion by plasmacytoid dendritic cells |
| CD300e | CMRF35L, CLM-2, CMRF35-A5 | Prevents apoptosis, triggers the production of pro-inflammatory cytokines and upregulates the expression of cell surface co-stimulatory molecules |
| CD301 | MGL, HML, CLEC10A, MGL1 | Cell adhesion, cell-cell signaling and cellular recognition through glycoprotein binding |
| CD302 | DCL1, BIMLEC | Cell adhesion and migration |
| CD303 | ||
| CD304 | BDCA4, neuropilin 1, CLEC4C, NRP1 | Angiogensis, axon guidance, cell survival, migration, and invasion |
| CD305 | LAIR1 | Negative regulator of NK, B, and T cells |
| CD306 | LAIR2 | Inhibits cellular activation and inflammation |
| CD307 | IRTA2, FCRL5 | May function in B-cells activation and differentiation |
| CD309 | VEGFR2, KDR, FLK-1 | Activation of this receptor by VEGF plays a role in angiogenesis, development, wound healing, cell proliferation, migration and differentiation |
| CD312 | ||
| CD314 | NKG2D, KLRK1 | Receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells |
| CD315 | PTGFRN, CD9P-1, EWI-F, FPRP, SMAP-6 | Inhibits binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor. |
| CD316 | EWI2, PGRL, CD81P3, KASP,IGSF8, EWI-2, KCT-4 | Negative regulator of cell motility. |
| CD317 | BST2, HM1.24 | IFN-induced antiviral host restriction factor |
| CD318 | CDCP1, SIMA135 | Cell differentiation, homing and dissemination. May also have a pro-survival role |
| CD319 | CRACC, SLAMF7 | Mediates NK cell activation and may play a role in lymphocyte adhesion |
| CD320 | FDC-SM-8D6, TCbIR, 8D6 antigen | Augments the proliferation of plasma cell precursors generated by IL10. Receptor for the cellular uptake of transcobalamin bound cobalamin |
| CD321 | JAM-A, JAM-1, PAM-1, F11R | Plays a role in epithelial tight junction formation, regulation of leukocyte erythrocytes. migration, epithelial barrier maintenance and platelet activation |
| CD322 | JAM-B, JAM-2, VE-JAM | May play a role in lymphocyte homing to secondary lymphoid organs |
| CD324 | E-Cadherin, Uvomorulin, CDH1, E-cad | Calcium-dependent cell adhesion protein |
| CDw325 | ||
| CD326 | Ep-CAM, Ly74, EGP314, TROP-1, TACSTD1 | A homotypic calcium-independent T-cell adhesion molecule |
| CDw327 | ||
| CDw328 | ||
| CDw329 | ||
| CD331 | FGFR1, Fms-like tyrosine kinase-2, KAL2, N-SAM | Receptor for basic fibroblast growth factor. |
| CD332 | FGFR2, BEK, KGFR | Cell-surface receptor for fibroblast growth factors |
| CD333 | FGFR3, ACH, CEK2 | Cell-surface receptor for fibroblast growth factors |
| CD334 | FGFR4, JTK2, TKF | Cell-surface receptor for fibroblast growth factors |
| CD335 | ||
| CD336 | NKp44, Ly-95 homolog, NCR2 | Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated NK cells to mediate tumor cell lysis |
| CD337 | NKp30, Ly117, NCR3 | Cytotoxicity-activating receptor that contributes to the increased efficiency ofactivated NK cells to mediate tumor cell lysis |
| CDw338 | ||
| CD339 | Jagged-1, JAG1, JAGL1, hJ1 | Ligand for multiple Notch receptors. Involved in the mediation of Notch signaling, cell fate determination in hematopoiesis and cardiovascular development |
